International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 61

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 61

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 61

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acidum levomefolicum

levomefolic acid

N-(4-{[(2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid

acide lévoméfolique

acide *N*-[4-({[(6*S*)-2-amino-5-méthyl-4-oxo-1,4,5,6,7,8-hexahydroptéridin-6-yl]methyl}amino)benzoyl]-L-glutamique

ácido levomefólico

ácido *N*-(4-{[(2-amino-5-metil-4-oxo-3,4,5,6,7,8-hexahidropteridin-6-il)metil]amino}benzoilo)-L-glutámico

$C_{20}H_{25}N_7O_6$



aderbasibum

aderbasib

methyl (6*S*,7*S*)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate

aderbasib

(6*S*,7*S*)-7(hydroxycarbamoyl)-6-[(4-phénylpipérazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate de méthyle

aderbasib

(6*S*,7*S*)-6-(4-fenilpiperazina-1-carbonil)-7-(hidroxicarbamoil)-5-azaspiro[2.5]octano-4-carboxilato de metilo

$C_{21}H_{28}N_4O_5$



adoprazinum

adoprazine	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophenyl)pyridin-3-yl]methyl}piperazine
adoprazine	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophényl)pyridin-3-yl]méthyl}pipérazine
adoprazina	1-(2,3-dihidro-1,4-benzodioxin-5-il)-4-{[5-(4-fluorofenil)piridin-3-il]metil}piperazina

$C_{24}H_{24}FN_3O_2$



alipogenum tiparvovecum #

alipogene tiparvovec	recombinant adeno-associated virus serotype 1 (AAV1) vector expressing the S447X variant of the human lipoprotein lipase (LPL) gene
alipogène tiparvovec	vecteur adéno-associated virus de type 1 (AAV1) recombinant exprimant le variant S447X du gène humain de la lipoprotéine lipase (demander confirmation de la traduction à MPL et RBD)
alipogén tiparvovec	vector viral adeno-asociado recombinante de tipo 1 (AAV1) que expresa la variante S447X del gen humano de lipoproteina lipasa (LPL)

apricoxibum

apricoxib	4-[2-(4-ethoxyphenyl)-4-methyl-1*H*-pyrrol-1-yl]benzenesulfonamide
apricoxib	4-[2-(4-éthoxyphényl)-4-méthyl-1*H*-pyrrol-1-yl]benzènesulfonamide
apricoxib	4-[2-(4-etoxifenil)-4-metil-1*H*-pirrol-1-il]bencenosulfonamida

$C_{19}H_{20}N_2O_3S$



bafetinibum

bafetinib — *N*-{3-[([5,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3*S*)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide

bafétinib — *N*-[3-([5,5'-bipyrimidin]-2-ylamino)-4-méthylphényl]-4-{[(3*S*)-3-(diméthylamino)pyrrolidin-1-yl]méthyl}-3-(trifluorométhyl)benzamide

bafetinib — *N*-{3-[([5,5'-bipirimidin]-2-il)amino]-4-metilfenil}-4-{[(3*S*)-3-(dimetilamino)pirrolidin-1-il]metil}-3-(trifluorometil)benzamida

$C_{30}H_{31}F_3N_8O$



bederocinum

bederocin — 2-{[3-({[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methyl}amino)propyl]amino}quinolin-4(1*H*)-one

bédérocine — 2-{[3-({[4-bromo-5-(1-fluoroéthényl)-3-méthylthiophén-2-yl]méthyl}amino)propyl]amino}quinoléin-4(1*H*)-one

bederocina — 2-{[3-({[4-bromo-5-(1-fluoroetenil)-3-metiltiofen-2-il]metil}amino)propil]amino}quinolin-4(1*H*)-ona

$C_{20}H_{21}BrFN_3OS$



befiradolum

befiradol — (3-chloro-4-fluorophenyl)[4-fluoro-4-({[(5-methylpyridin-2-yl)methyl]amino}methyl)piperidin-1-yl]methanone

béfiradol — (3-chloro-4-fluorophényl)[4-fluoro-4-({[(5-méthylpyridin-2-yl)méthyl]amino}méthyl)pipéridin-1-yl]méthanone

befiradol — (3-cloro-4-fluorofenil){4-fluoro-4-[({(5-metilpiridin-2-il)metil}amino)metil]piperidin-1-il}metanona

$C_{20}H_{22}ClF_2N_3O$



bevasiranibum

bevasiranib

siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production
duplex of thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanosine and thymidylyl-(3'→5')-thymidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenosine

bévasiranib

petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de l'endothélium vasculaire (VEGF)
duplex de thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanosine et thymidylyl-(3'→5')-thymidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénosine

bevasiranib

ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor vascular de crecimiento endotelial (VEGF)
duplex de timidilil-(3'→5')-timidilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanosina y timidilil-(3'→5')-timidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenosina

$C_{401}H_{502}N_{153}O_{290}P_{40}$

(3'-5') dT−dT−U−G−G−A−G−U−G−G−U−U−C−C−G−G−U−C−G−U−G
(5'-3') A−C−C−U−C−A−C−C−A−A−G−G−C−C−A−G−C−A−C−dT−dT

catridecacogum #

catridecacog

human Factor XIII [A_2] homodimer (allele F13A*1B), recombinant DNA origin

catridécacog

chaîne A du facteur XIII de coagulation humain non-activée (allèle F13A*1B), homodimère, origine ADN recombinant

catridecacog

cadena A del factor XIII de coagulación humano no activado (alelo F13A*1B), homodímero, origen ADN recombinante

$C_{3708}H_{5735}N_{1013}O_{1111}S_{28}$

```
SETSRTAFGG RRAVPPNNSN AAEDDLPTVE LQGVVPRGVN LQEFLNVTSV 50
HLFKERWDTN KVDHHTDKYE NNKLIVRRGQ SFYVQIDFSR PYDPRRDLFR 100
VEYVIGRYPQ ENKGTYIPVP IVSELQSGKW GAKIVMREDR SVRLSIQSSP 150
KCIVGKFRMY VAVWTPYGVL RTSRNPETDT YILFNPWCED DAVYLDNEKE 200
REEYVLNDIG VIFYGEVNDI KTRSWSYGQF EDGILDTCLY VMDRAQMDLS 250
GRGNPIKVSR VGSAMVNAKD DEGVLVGSWD NIYAYGVPPS AWTGSVDILL 300
EYRSSENPVR YGQCWVFAGV FNTFLRCLGI PARIVTNYFS AHDNDANLQM 350
DIFLEEDGNV NSKLTKDSVW NYHCWNEAWM TRPDLPVGFG GWQAVDSTPQ 400
ENSDGMYRCG PASVQAIKHG HVCFQFDAPF VFAEVNSDLI YITAKKDGTH 450
VVENVDATHI GKLIVTKQIG GDGMMDITDT YKFQEGQEEE RLALETALMY 500
GAKKPLNTEG VMKSRSNVDM DFEVENAVLG KDFKLSITFR NNSHNRYTIT 550
AYLSANITFY TGVPKAEFKK ETFDVTLEPL SFKKEAVLIQ AGEYMGQLLE 600
QASLHFFVTA RINETRDVLA KQKSTVLTIP EIIIKVRGTQ VVGSDMTVTV 650
EFTNPLKETL RNVWVHLDGP GVTRPMKKMF REIRPNSTVQ WEEVCRPWVS 700
GHRKLIASMS SDSLRHVYGE LDVQIQRRPS M                     731
```

Modified residues / Résidus modifiés / Residuos modificados



citatuzumabum bogatoxum #

citatuzumab bogatox

immunoglobulin Fab fusion protein, anti-[*Homo sapiens* tumor-associated calcium signal transducer 1 (TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, CD326)], humanized Fab fused with *Bougainvillea spectabilis Willd* rRNA N-glycosidase [type I ribosome inactivating protein (RIP), bouganin], VB6-845; gamma1 heavy chain fragment (1-225) [hexahistidyl (1-6) -humanized VH from 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01, V124>L) [8.8.9] (7-122) -*Homo sapiens* IGHG1*01 CH1-hinge fragment EPKSC (123-225)], (225-219')-disulfide with kappa fusion chain (1'-481') [humanized V-KAPPA from clone 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ1*01, I126>L) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219') -12-mer furin linker (proteolytic cleavage spacer from Pseudomonas exotoxin A) (220'-231') -*Bougainvillea spectabilis Willd* bouganin fragment (27-276 from precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

citatuzumab bogatox

immunoglobuline Fab protéine de fusion, anti-[*Homo sapiens* transducteur 1 du signal calcium associé aux tumeurs (TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, molécule d'adhésion de la cellule épithéliale Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, CD326)], humanisé Fab fusionné avec la N-glycosidase de l'ARNr [protéine de type I inactivant le ribosome (RIP), bouganine] de *Bougainvillea spectabilis Willd*, VB6-845; fragment de chaîne lourde gamma1 (1-225) [hexahistidyl (1-6) -VH humanisé de 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01, V124>L) [8.8.9] (7-122) -*Homo sapiens* IGHG1*01 CH1-fragment de la charnière EPKSC (123-225)], (225-219')-disulfure avec la chaîne kappa de fusion (1'-481') [V-KAPPA humanisé du clone 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ1*01, I126>L) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219') -12-mer furin linker (motif de clivage protéolytique de Pseudomonas exotoxin A) (220'-231') -*Bougainvillea spectabilis Willd* bouganine fragment (27-276 du précurseur, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

citatuzumab bogatox

inmunoglobulina Fab proteina de fusión, anti-[*Homo sapiens* transductor 1 de la señal de calcio asociado a tumores (TACSTD1, proteina 2 asociada a tumores gastrointestinales, GA733-2, glicoproteíne epitelial 2, EGP-2, molécula de adhesión de la célula epitelial Ep-CAM, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, CD326)], humanizado Fab fusionado con la N-glicosidasa de ARNr [proteína de tipo I inactivadora del ribosoma (RIP), buganina] de *Bougainvillea spectabilis Willd*, VB6-845; fragmento de cadena pesada gamma1 (1-225) [hexahistidil (1-6) -VH humanizado de 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01, V124>L) [8.8.9] (7-122) -*Homo sapiens* IGHG1*01 CH1-fragmento de la bisagra EPKSC (123-225)], (225-219')-disulfuro con la cadena kappa de fusión (1'-481') [V-KAPPA humanizado del clon 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ1*01, I126>L) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219') -12-*mer* ligante de furina (espaciador de ruptura proteolítica de Pseudomonas exotoxin A) (220'-231') – buganina de *Bougainvillea spectabilis Willd* fragmento (27-276 del precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

$C_{3455}H_{5371}N_{921}O_{1060}S_{18}$

Heavy chain / Chaîne lourde / Cadena pesada

HHHHHHEVQL	VQSGPGLVQP	GGSVRISCAA	SGYTFTNYGM	NWVKQAPGKG 50
LEWMGWINTY	TGESTYADSF	KGRFTFSLDT	SASAAYLQIN	SLRAEDTAVY 100
YCARFAIKGD	YWGQGTLLTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL 150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT 200
QTYICNVNHK	PSNTKVDKKV	EPKSC		225

Light chain-toxin / Chaîne légère-toxine / Cadena ligera-toxina

DIQMTQSPSS	LSASVGDRVT	ITCRSTKSLL	HSNGITYLYW	YQQKPGKAPK 50'
LLIYQMSNLA	SGVPSRFSSS	GSGTDFTLTI	SSLQPEDFAT	YYCAQNLEIP 100'
RTFGQGTKVE	LKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK 150'
VQWKVDNALQ	SGNSQESVTE	QDSKDSTYSL	SSTLTLSKAD	YEKHKVYACE 200'
VTHQGLSSPV	TKSFNRGECT	RHRQPRGWEQ	LYNTVSFNLG	EAYEYPTFIQ 250'
DLRNELAKGT	PVCQLPVTLQ	TIADDKRFVL	VDITTTSKKT	VKVAIDVTDV 300'
YVVGYQDKWD	GKDRAVFLDK	VPTVATSKLF	PGVTNRVTLT	FDGSYQKLVN 350'
AAKADRKALE	LGVNKLEFSI	EAIHGKTING	QEAAKFFLIV	IQMVSEAARF 400'
KYIETEVVDR	GLYGSFKPNF	KVLNLENNWG	DISDAIHKSS	PQCTTINPAL 450'
QLISPSNDPW	VVNKVSQISP	DMGILKFKSS	K	481'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
23'-93' 28-102 139'-199' 149-205 219'-225 263'-443'

conatumumabum #
conatumumab

immunoglobulin G1, anti-[*Homo sapiens* tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, TR-2, CD262)], *Homo sapiens* monoclonal antibody, XG1-048 v w (or AMG 655, TRAIL-R2mAb); gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (231-231'':234-234'')-bisdisulfide dimer

conatumumab

immunoglobuline G1, anti-[*Homo sapiens* membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale (TNFRSF10B, death receptor 5, DR5, TRAIL-R2, TR-2, CD262)], *Homo sapiens* anticorps monoclonal, XG1-048 v w (ou AMG 655, TRAIL-R2mAb); chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (231-231'':234-234'')-bisdisulfure

conatumumab

inmunoglobulina G1, anti-[*Homo sapiens* miembro 10B de la superfamilia de receptores del factor de necrosis tumoral (TNFRSF10B, receptor mortal 5, DR5, TRAIL-R2, TR-2, CD262)], *Homo sapiens* anticorps monoclonal, XG1-048 v w (o AMG 655, TRAIL-R2mAb); cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (231-231'':234-234'')-bisdisulfuro

$C_{6466}H_{10006}N_{1730}O_{2024}S_{40}$

Heavy γ1-chain / Chaîne lourde γ1 / Cadena pesada γ1

```
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYFWSWIR QLPGKGLEWI  50
GHIHNSGTTY YNPSLKSRVT ISVDTSKKQF SLRLSSVTAA DTAVYYCARD 100
RGGDYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light κ-chain / Chaîne légère κ / Cadena ligera κ

```
EIVLTQSPGT LSLSPGERAT LSCRASQGIS RSYLAWYQQK PGQAPSLLIY  50'
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QFGSSPWTFG 100'
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150'
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200'
GLSSPVTKSF NRGEC                                        215'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-97    22"-97"    23'-89'    23'"-89'"  135'-195'  135'"-195'"  149-205  149"-205"
215'-225 215'"-225" 231-231"   234-234"   266-326    266"-326"    372-430  372"-430"
```

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

```
N =  Asn-302  Asn-302"
```

custirsenum

custirsen

2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridine

custirsen

2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridine

custirsén

2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridll-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridina

$C_{231}H_{312}N_{78}O_{119}P_{20}S_{20}$

(3' 5')d(P-thio)(r<u>C</u>-r<u>A</u>-r<u>G</u>-r<u>C</u>-A-G-C-A-G-A-G-T-C-T-T-C-A-r<u>U</u>-r<u>C</u>-r<u>A</u>-r<u>U</u>)
Modified nucleosides
<u>A</u> = 2'-O-(2-methoxyethyl)adenosine
<u>C</u> = 2'-O-(2-methoxyethyl)-5-methylcytidine
<u>G</u> = 2'-O-(2-methoxyethyl)guanosine
<u>U</u> = 2'-O-(2-methoxyethyl)-5-methyluridine

danusertibum

danusertib

N-{5-[(2*R*)-2-methoxy-2-phenylacetyl]-1,4,5,6-tetrahydropyrrolo[3,4-*c*]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide

danusertib

N-{5-[(2*R*)-2-méthoxy-2-phénylacétyl]-1,4,5,6-tétrahydropyrrolo[3,4-*c*]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl)benzamide

danusertib

N-{5-[(2*R*)-2-fenil-2-metoxiacetil]-1,4,5,6-tetrahidropirrolo[3,4-*c*]pirazol-3-il}-4-(4-metilpiperazin-1-il)benzamida

$C_{26}H_{30}N_6O_3$



darotropii bromidum

darotropium bromide

(1*R*,3*r*,5*S*)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide

bromure de darotropium

bromure de (1*R*,3*r*,5*S*)-3-(2-cyano-2,2-diphényléthyl)-8,8-diméthyl-8-azabicyclo[3.2.1]octan-8-ium

bromuro de darotropio

bromuro de (1*R*,3*r*,5*S*)-3-(2-ciano-2,2-difeniletil)-8,8-dimetil-8-azabiciclo[3.2.1]octan-8-io

$C_{24}H_{29}BrN_2$



demiditrazum

demiditraz

2-[(1*S*)-1-(2,3-dimethylphenyl)ethyl]-1*H*-imidazole

démiditraz

2-[(1*S*)-1-(2,3-diméthylphényl)éthyl]-1*H*-imidazole

demiditraz

2-[(1*S*)-1-(2,3-dimetilfenil)etil]-1*H*-imidazol

$C_{13}H_{16}N_2$



denenicokinum

denenicokin

recombinant L-methionyl(human interleukin-21) (134 amino acids), produced in *Escherichia coli*

dénénicokine

L-méthionyl(interleukine-21 humaine), recombinante (134 acides aminés), produite par *Escherichia coli*

denenicokina

L-metionil(interleukina-21 humana), recombinante (134 aminoácido), producida por *Escherichia coli*

$C_{676}H_{1087}N_{205}O_{203}S_8$

```
                                                                M
QGQDRHMIRM  RQLIDIVDQL  KNYVNDLVPE  FLPAPEDVET  NCEWSAFSCF 50
QKAQLKSANT  GNNERIINVS  IKKLKRKPPS  TNAGRRQKHR  LTCPSCDSYE 100
KKPPKEFLER  FKSLLQKMIH  QHLSSRTHGS  EDS                    133
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
42-93 49-96

derquantelum

derquantel

(1'*R*,5a'*S*,7'*R*,8a'*S*,9a'*R*)-1'-hydroxy-1',4,4,8',8',11'-hexamethyl-2',3',8a',9,9',10-hexahydro-4*H*,1'*H*,5'*H*,6'*H*,8'*H*-spiro[[1,4]dioxepino[2,3-*g*]indole-8,7'-[5a,9a](epiminomethano)cyclopenta[*f*]indolizin]-10'-one

derquantel (1'*R*,5'a*S*,7'*R*,8'a*S*,9'a*R*)-1'-hydroxy-1',4,4,8',8',11'-hexaméthyl-2',3',8'a,9,9',10-hexahydro-1'*H*,4*H*,5'*H*,6'*H*,8'*H*-spiro[[1,4]dioxépino[2,3-*g*]indole-8,7'-[5a,9a](épiminométhano)cyclopenta[*f*]indolizin]-10'-one

derquantel (1'*R*,5a'*S*,7'*R*,8a'*S*,9a'*R*)-1'-hidroxi-1',4,4,8',8',11'-hexametil-2',3',8a',9,9',10-hexahidro-4*H*,1'*H*,5'*H*,6'*H*,8'*H*-espiro[[1,4]dioxepino[2,3-*g*]indol-8,7'-[5a,9a](epiminometano)ciclopenta[*f*]indolizin]-10'-ona

$C_{28}H_{37}N_3O_4$



disitertidum

disitertide human Transforming Growth Factor-beta receptor type III-(710-723)-peptide

disitertide récepteur de type III du facteur de croissance transformant-bêta humain-(710-723)-peptide

disitertida receptor de tipo III del factor de crecimiento transformador-beta humano-(710-723)-péptido

$C_{68}H_{109}N_{17}O_{22}S_2$

H-Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn-OH
10 14

drinabantum

drinabant *N*-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-*N*-(3,5-difluorophenyl)methanesulfonamide

drinabant *N*-{1-[bis(4-chlorophényl)méthyl]azétidin-3-yl}-*N*-(3,5-difluorophényl)méthanesulfonamide

drinabant *N*-{1-[bis(4-clorofenil)metil]azetidin-3-il}-*N*-(3,5-difluorofenil)metanosulfonamida

$C_{23}H_{20}Cl_2F_2N_2O_2S$



dulanerminum

dulanermin

human tumor necrosis factor ligand superfamily member 10 (TNF-related apoptosis-inducing ligand or Apo-2 ligand or CD253 antigen)-(114-281)-peptide (*C*-terminal part of the extracellular domain), noncovalent homotrimer

dulanermine

membre 10 de la superfamille de ligand du facteur de nécrose tumorale humain (ligand inducteur d'apoptose apparenté au TNF ou Apo-2 ligand ou antigène CD253)-(114-281)-peptide (extrémité -terminale du domaine extracellulaire), homotrimère nonacovalent

dulanermina

miembro 10 de la superfamilia de ligandos del factor de necrosis tumoral humano (ligando inductor de apoptosis relacionada con el TNF o Apo-2 ligand o antígeno CD253)-(114-281)-péptido (extremo *C*-terminal del dominio extracelular), homotrímero nonacovalente

$C_{871}H_{1329}N_{243}O_{260}S_4$

Monomer

```
VRERGPQRVA  AHITGTRGRS  NTLSSPNSKN  EKALGRKINS  WESSRSGHSF  50
LSNLHLRNGE  LVIHEKGFYY  IYSQTYFRFQ  EEIKENTKND  KQMVQYIYKY  100
TSYPDPILLM  KSARNSCWSK  DAEYGLYSIY  QGGIFELKEN  DRIFVSVTNE  150
HLIDMDHEAS  FFGAFLVG                                       168
```

edoxabanum

edoxaban

N-(5-chloropyridin-2-yl)-*N'*-[(1*S*,2*R*,4*S*)-4-(*N,N*-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-*c*]pyridine-2-carboxamido)cyclohexyl]oxamide

édoxaban

N-(5-chloropyridin-2-yl)-*N'*-[(1*S*,2*R*,4*S*)-4-(*N,N*-diméthylcarbamoyl)-2-(5-méthyl-4,5,6,7-tétrahydro[1,3]thiazolo[5,4-*c*]pyridine-2-carboxamido)cyclohexyl]oxamide

edoxabán

N-(5-cloropiridin-2-il)-*N'*-[(1*S*,2*R*,4*S*)-4-(*N,N*-dimetilcarbamoil)-2-(5-metil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-*c*]piridina-2-carboxamido)ciclohexil]oxamida

$C_{24}H_{30}ClN_7O_4S$



elagolixum

elagolix

4-({(1*R*)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2*H*)-yl)-1-phenylethyl}amino)butanoic acid

élagolix — acide 4-({(1*R*)-2-[5-(2-fluoro-3-méthoxyphényl)-3-{[2-fluoro-6-(trifluorométhyl)phényl]méthyl}-4-méthyl-2,6-dioxo-3,6-dihydropyrimidin-1(2*H*)-yl]-1-phényléthyl}amino)butanoïque

elagolix — ácido 4-({(1*R*)-2-[5-(2-fluoro-3-metoxifenil)-3-{[2-fluoro-6-(trifluorometil)fenil]metil}-4-metil-2,6-dioxo-3,6-dihidropirimidin-1(2*H*)-il)-1-feniletil}amino)butanoico

$C_{32}H_{30}F_5N_3O_5$



elesclomolum

elesclomol — *N,N*′-dimethyl-*N,N*′-di(benzenecarbonothioyl)propanedihydrazide

élesclomol — 1-*N*′,3-*N*′-diméthyl-1-*N*′,3-*N*′-dibenzènecarbonothioylpropanedihydrazide

elesclomol — *N,N*′-dimetil-*N,N*′-di(bencenocarbonotioil)propanodihidrazida

$C_{19}H_{20}N_4O_2S_2$



entinostatum

entinostat — (pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl} methyl)carbamate

entinostat — ({4-[(2-aminophényl)carbamoyl]phényl}méthyl)carbamate de pyridin-3-ylméthyle

entinostat — ({4-[(2-aminofenil)carbamoil]fenil}metil)carbamato de (piridin-3-il)metilo

$C_{21}H_{20}N_4O_3$



eprotiromum

eprotirome — 3-({3,5-dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}amino)-3-oxopropanoic acid

éprotirome — acide 3-({3,5-dibromo-4-[4-hydroxy-3-(1-méthyléthyl)phénoxy]phényl}amino)-3-oxopropanoïque

eprotiromo — ácido 3-({3,5-dibromo-4-[4-hidroxi-3-(propan-2-il)fenoxi]fenil}amino)-3-oxopropanoico

$C_{18}H_{17}Br_2NO_5$



esreboxetinum

esreboxetine — (2*S*)-2-[(2-ethoxyphenoxy)(phenyl)methyl]morpholine

esréboxétine — (+)-(2*S*)-2-[(*S*)-(2-éthoxyphénoxy)phénylméthyl]morpholine

esreboxetina — (2*S*)-2-[(2-etoxifenoxi)(fenil)metil]morfolina

$C_{19}H_{23}NO_3$



etaracizumabum #

etaracizumab — immunoglobulin G1, anti-[*Homo sapiens* alphaVbeta3 integrin (CD51/CD61, CD51/GPIIIa, CD51/platelet membrane glycoprotein IIIa, vitronectin receptor)], humanized monoclonal antibody, MEDI-522 (or hLM609); gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR from clone LM609-*Homo sapiens* IGHJ5*01, L123>T) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR from clone LM609-*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (226-226":230-230")-bisdisulfide dimer

étaracizumab — immunoglobuline G1, anti-[*Homo sapiens* alphaVbeta3 intégrine (CD51/CD61, CD51/GPIIIa, CD51/glycoprotéine membranaire IIIa des plaquettes, récepteur de la vitronectine)], anticorps monoclonal humanisé, MEDI-522 (ou hLM609); chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR du clone LM609-*Homo sapiens* IGHJ5*01, L123>T) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR du clone LM609-*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (226-226":230-230")-bisdisulfure

etaracizumab

inmunoglobulina G1, anti-[*Homo sapiens* alfaVbeta3 integrina (CD51/CD61, CD51/GPIIIa, CD51/glicoproteina IIIa de membrana de plaquetas, receptor de la vitronectina)], anticuerpo monoclonal humanizado, MEDI-522 (o hLM609); cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR del clon LM609-*Homo sapiens* IGHJ5*01, L123>T) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* FR/*Mus musculus* CDR del clon LM609-*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (226-226":230-230")-bisdisulfuro

$C_{6392}H_{9908}N_{1732}O_{1996}S_{42}$

γ–Heavy chain/ Chaîne γ lourde / Cadena γ pesada

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYDMSWVRQA	PGKGLEWVAK	50
VSSGGGSTYY	LDTVQGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARHL	100
HGSFASWGQG	TTVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	SSLGTQTYIC	200
NVNHKPSNTK	VDKRVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTPPVLDS	400
DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSLSPGK	447

κ–Light chain / Chaîne κ légère/ Cadena κ ligera

EIVLTQSPAT	LSLSPGERAT	LSCQASQSIS	NFLHWYQQRP	GQAPRLLIRY	50'
RSQSISGIPA	RFSGSGSGTD	FTLTISSLEP	EDFAVYYCQQ	SGSWPLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96	22"-96"	23'-88'	23'"-88'"	134'-194'	134'"-194'"	144-200	144"-200"
214'-220	214'"-220"	226-226"	229-229"	261-321	261"-321"	367-425	367"-425"

foravirumabum #

foravirumab

immunoglobulin G1-kappa, anti-[rabies virus glycoprotein], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

foravirumab

immunoglobuline G1-kappa, anti-[glycoprotéine du virus de la rage], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

foravirumab

inmunoglobulina G1-kappa, anti-[glicoproteína del virus de la rabia], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

$C_{6400}H_{9914}N_{1718}O_{1998}S_{44}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG AVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV  50
ILYDGSDKFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVA 100
VAGTHFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LNSYPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    146-202   263-323   369-427
         22"-96"  146"-202" 263"-323" 369"-427"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L 222-214' 222"-214'"
Inter-H-H 228-228" 231-231"
```

N-glycosylation sites / Sites de *N*-glycosylation / Posiciones de *N*-glicosilación
299, 299"

ibipinabantum
ibipinabant

(*E*,4*S*)-*N*′-(4-chlorobenzenesulfonyl)-3-(4-chlorophenyl)-*N*-methyl-4-phenyl-4,5-dihydro-1*H*-pyrazole-1-carboximidamide

ibipinabant

(*E*,4*S*)-*N*′-(4-chlorobenzènesulfonyl)-3-(4-chlorophényl)-*N*-méthyl-4-phényl-4,5-dihydro-1*H*-pyrazole-1-carboximidamide

ibipinabant

(*E*,4*S*)-*N*′-(4-clorobencenosulfonil)-3-(4-clorofenil)-4-fenil-*N*-metil-4,5-dihidro-1*H*-pirazol-1-carboximidamida

$C_{23}H_{20}Cl_2N_4O_2S$



intiquinatinum

intiquinatine (2*R*)-2-{4-[(7-bromoquinolin-2-yl)oxy]phenoxy}propanoic acid

intiquinatine acide (2*R*)-2-{4-[(7-bromoquinoléin-2-yl)oxy]phénoxy}propanoïque

intiquinatina ácido (2*R*)-2-{4-[(7-bromoquinolin-2-il)oxi]fenoxi}propanoico

$C_{18}H_{14}BrNO_4$



lancovutidum

lancovutide ($C^{3,15}R$)-$C^{3,15}$-hydroxy[2-L-lysine,10-L-phenylalanine, 12-L-phenylalanine-,13-L-valine]lantibiotic ancovenin (*Streptomyces* sp)

lancovutide ($C^{3,15}R$)-$C^{3,15}$-hydroxy[2-L-lysine,10-L-phénylalanine, 12-L-phénylalanine-,13-L-valine]ancovénine antibiotique (*Streptomyces* sp)

lancovutida $C^{3,15}R$)-$C^{3,15}$-hidroxi[2-L-lisina,10-L-fenilalanina,12-L-fenilalanina-, 13-L-valina]ancovenina antibiótico (*Streptomyces* sp)

$C_{89}H_{125}N_{23}O_{25}S_3$



larazotidum

larazotide glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine

larazotide glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine

larazotida glicilglicil-L-valil-L-leucil-L-valil-L-glutaminil-L-prolilglicina

$C_{32}H_{55}N_9O_{10}$

H–Gly—Gly—Val—Leu—Val—Gln—Pro—Gly–OH

lensiprazinum

lensiprazine (2*R*)-8-{4-[3-(5-fluoro-1*H*-indol-3-yl)propyl]piperidin-1-yl}-2-methyl-2*H*-1,4-benzooxazin-3(4*H*)-one

lensiprazine (-)-(2*R*)-8-{4-[3-(5-fluoro-1*H*-indol-3-yl)propyl]pipérazin-1-yl}-2-méthyl-2*H*-1,4-benzoxazin-3(4*H*)-one

lensiprazina (2*R*)-8-{4-[3-(5-fluoro-1*H*-indol-3-il)propil]piperidin-1-il}-2-metil-2*H*-1,4-benzooxazin-3(4*H*)-ona

$C_{24}H_{27}FN_4O_2$



levomilnacipranum

levomilnacipran	(1*S*,2*R*)-2-(aminomethyl)-*N*,*N*-diethyl-1-phenylcyclopropanecarboxamide
lévomilnacipran	(-)-(1*S*,2*R*)-2-(aminométhyl)-*N*,*N*-diéthyl-1-phénylcyclopropanecarboxamide
levomilnaciprán	(-)-(1*S*,2*R*)-2-(aminometil)-*N*,*N*-dietil-1-fenilciclopropanocarboxamida

$C_{15}H_{22}N_2O$



linagliptinum

linagliptin	8-[(3*R*)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1*H*-purine-2,6-dione
linagliptine	8-[(3*R*)-3-aminopipéridin-1-yl]-7-(but-2-yn-1-yl)-3-méthyl-1-[(4-méthylquinazolin-2-yl)méthyl]-3,7-dihydro-1*H*-purine-2,6-dione
linagliptina	8-[(3*R*)-3-aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil-1-[(4-metilquinazolin-2-il)metil]-3,7-dihidro-1*H*-purina-2,6-diona

$C_{25}H_{28}N_8O_2$



lixisenatidum

lixisenatide	des-38-proline-exendine-4 (*Heloderma suspectum*)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide
lixisénatide	dés-38-proline-exendine-4 (*Heloderma suspectum*)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide
lixisenatida	des-38-prolina-exendina-4 (*Heloderma suspectum*)-(1-39)-peptidilpenta-L-lisil-L-lisinamida

$C_{215}H_{347}N_{61}O_{65}S$

H–His–Gly–Glu–Gly–Thr–Phe–Thr–Ser–Asp–Leu–Ser–Lys–Gln–Met–
10
Glu–Glu–Glu–Ala–Val–Arg–Leu–Phe–Ile–Glu–Trp–Leu–Lys–Asn–
20
Gly–Gly–Pro–Ser–Ser–Gly–Ala–Pro–Pro–Ser–Lys–Lys–Lys–Lys–
30 40
Lys–Lys–NH_2
44

macitentanum

macitentan — *N*-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]ethoxy}pyrimidin-4-yl]-*N'*-propylsulfuric diamide

macitentan — *N*-[5-(4-bromophényl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]éthoxy}pyrimidin-4-yl]-*N'*-propyldiamide sulfurique

macitentán — *N*-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]etoxi}pirimidin-4-il]-*N'*-propildiamida sulfúrica

$C_{19}H_{20}Br_2N_6O_4S$



melogliptinum

melogliptin — (2*S*,4*S*)-4-fluoro-1-[2-({(1*R*,3*S*)-3-[(1*H*-1,2,4-triazol-1-yl)methyl]cyclopentyl}amino)acetyl]pyrrolidine-2-carbonitrile

mélogliptine — (2*S*,4*S*)-4-fluoro-1-[2-({(1*R*,3*S*)-3-[(1*H*-1,2,4-triazol-1-yl)méthyl]cyclopentyl}amino)acétyl]pyrrolidine-2-carbonitrile

melogliptina — (2*S*,4*S*)-4-fluoro-1-[2-({(1*R*,3*S*)-3-[(1*H*-1,2,4-triazol-1-il)metil]ciclopentil}amino)acetil]pirrolidina-2-carbonitrilo

$C_{15}H_{21}FN_6O$



mimopezilum

mimopezil

(5*R*,9*R*)-5-{[(5-chloro-2-hydroxy-3-methoxyphenyl)methylidene]amino}-11-[(*E*)-ethylidene]-7-methyl-5,6,9,10-tetrahydro-5,9-methanocycloocta[*b*]pyridin-2(1*H*)-one

mimopézil

(5*R*,9*R*)-5-{[(5-chloro-2-hydroxy-3-méthoxyphényl)méthylidène]amino}-11-[(*E*)-ethylidène]-7-méthyl-5,6,9,10-tétrahydro-5,9-méthanocycloocta[*b*]pyridin-2(1*H*)-one

mimopezilo

(5*R*,9*R*)-5-{[(5-cloro-2-hidroxi-3-metoxifenil)metilideno]amino}-11-[(*E*)-etilideno]-7-metil-5,6,9,10-tetrahidro-5,9-metanociclooctа[*b*]piridin-2(1*H*)-ona

$C_{23}H_{23}ClN_2O_3$



mipomersenum

mipomersen

antisense oligonucleotide inhibitor of apolipoprotein B (APOB) expression

2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidine

mipomersen

oligonucléotide antisens, inhibiteur de l'expression de l'apolipoprotéine B (APOB)

2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')*P*-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidine

mipomersén

oligonucleótido antisentido inhibidor de la expresión de la apolipoproteina B (APOB)
2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidina

$C_{230}H_{324}N_{67}O_{122}P_{19}S_{19}$

(3'-5')(P-thio)(G-C-C-U-C-dA-dG-dT-dC-dT-dG-dC-dT-dT-dC-G-C-A-C-C)

Modified nucleosides / Nucléosides modifiés / Nucleósidos modificados



niraxostatum

niraxostat

1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1*H*-pyrazole-4-carboxylic acid

niraxostat

acide 1-[3-cyano-4-(2,2-diméthylpropoxy)phényl]-1*H*-pyrazole-4-carboxylique

niraxostat

ácido 1-[3-ciano-4-(2,2-dimetilpropoxi)fenil]-1*H*-pirazol-4-carboxílico

$C_{16}H_{17}N_3O_3$



olesoximum

olesoxime (*EZ*)-*N*-(cholest-4-en-3-ylidene)hydroxylamine

olésoxime (*EZ*)-*N*-(cholest-4-én-3-ylidène)hydroxylamine

olesoxima (*EZ*)-*N*-(colest-4-en-3-ilideno)hidroxilamina

$C_{27}H_{45}NO$



ombrabulinum

ombrabulin (2*S*)-2-amino-3-hydroxy-*N*-{2-methoxy-5-[(1*Z*)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl}propanamide

ombrabuline (2*S*)-2-amino-3-hydroxy-*N*-{2-méthoxy-5-[(1*Z*)-2-(3,4,5-triméthoxyphényl)éthényl]phényl]propanamide

ombrabulina (2*S*)-2-amino-3-hidroxi-*N*-{2-metoxi-5-[(1*Z*)-2-(3,4,5-trimetoxifenil)etenil]fenil}propanamida

$C_{21}H_{26}N_2O_6$



otenabantum

otenabant 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9*H*-purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide

oténabant 1-[8-(2-chlorophényl)-9-(4-chlorophényl)-9*H*-purin-6-yl]-4-(éthylamino)pipéridine-4-carboxamide

otenabant 1-[8-(2-clorofenil)-9-(4-clorofenil)-9*H*-purin-6-il]-4-(etilamino)piperidina-4-carboxamida

$C_{25}H_{25}Cl_2N_7O$



palifosfamidum

palifosfamide — *N,N'*-bis(2-chloroethyl)phosphorodiamidic acid

palifosfamide — acide *N*,*N'*-bis(2-chloroéthyl)phosphorodiamidique

palifosfamida — ácido *N,N'*-bis(2-cloroetil)fosforodiamídico

$C_4H_{11}Cl_2N_2O_2P$



palovarotenum

palovarotene — 4-[(1*E*)-2-{5,5,8,8-tetramethyl-3-[(1*H*-pyrazol-1-yl)methyl]-5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl]benzoic acid

palovarotène — acide 4-{(1*E*)-2-[5,5,8,8-tétraméthyl-3-(1*H*-pyrazol-1-ylméthyl)-5,6,7,8-tétrahydronaphtalén-2-yl]éthényl}benzoïque

palovaroteno — ácido 4-[(1*E*)-2-{5,5,8,8-tetrametil-3-[(1*H*-pirazol-1-il)metil]-5,6,7,8-tetrahidronaftalen-2-il}etenil]benzoico

$C_{27}H_{30}N_2O_2$



radezolidum

radezolid — *N*-{[(5*S*)-3-(2-fluoro-4'-{[([1*H*-1,2,3-triazol-4-yl]methyl)amino]methyl}[1,1'-biphenyl]-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide

radézolid — *N*-{[(5*S*)-3-(2-fluoro-4'-{[(1*H*-1,2,3-triazol-4-ylméthyl)amino]méthyl}biphényl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]méthyl}acétamide

radezolid — *N*-{[(5*S*)-3-(2-fluoro-4'-{[([1*H*-1,2,3-triazol-4-il]metil)amino]metil}[1,1'-bifenil]-4-il)-2-oxo-1,3-oxazolidin-5-il]metil}acetamida

$C_{22}H_{23}FN_6O_3$



rafivirumabum #

rafivirumab — immunoglobulin G1-lambda, anti-[rabies virus glycoprotein], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfide with lambda light chain (1'-218') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; (236-236'':239-239'')-bisdisulfide dimer

rafivirumab — immunoglobuline G1-lambda, anti-[glycoprotéine du virus de la rage], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-456) [*Homo sapiens* VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfure avec la chaîne légère lambda (1'-218') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dimère (236-236'':239-239'')-bisdisulfure

rafivirumab — inmunoglobulina G1-lambda, anti-[glicoproteína del virus de la rabia], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-456) [*Homo sapiens* VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfuro con la cadena ligera lambda (1'-218') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dímero (236-236'':239-239'')-bisdisulfuro

$C_{6462}H_{9954}N_{1718}O_{2036}S_{46}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFN RYTVNWVRQA PGQGLEWMGG  50
IIPIFGTANY AQRFQGRLTI TADESTSTAY MELSSLRSDD TAVYFCAREN 100
LDNSGTYYYF SGWFDPWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPG                                                  456
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPRSV SGSPGQSVTI SCTGTSSDIG GYNFVSWYQQ HPGKAPKLMI  50
YDATKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC CSYAGDYTPG 100
VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150
TVAWKADSSP VKAGVETTTP SKQSNNKYAA SSYLSLTPEQ WKSHRSYSCQ 200
VTHEGSTVEK TVAPTECS                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    154-210    277-331    377-435
         22''-96''  154''-210''  277''-331''  377''-435''
Intra-L  22'-90'   140'-199'
         22'''-90'''  140'''-199'''
Inter-H-L  230-217'   230''-217'''
Inter-H-H  236-236''  239-239''
```

N-glycosylation sites / Sites de *N*-glycosylation / Posiciones de *N*-glicosilación
307, 307''

retaspimycinum

retaspimycin

(4*E*,6*Z*,8*S*,9S,10*E*,12*S*,13*R*,14*S*,16*R*)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docasa-1(21)4,6,10,18(22),19-hexaen-9-yl carbamate

rétaspimycine

carbamate de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13,20,22-trihydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3-oxo-19-(prop-2-énylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexén-9-yle

retaspimicina

carbamato de (4*E*,6*Z*,8*S*,9S,10*E*,12*S*,13*R*,14*S*,16*R*)-13,20,22-trihidroxi-4,10,12,16-tetrametil-8,14-dimetoxi-3-oxo-19-[(prop-2-en-1-il)amino]-2-azabiciclo[16.3.1]docasa-1(21)4,6,10,18(22),19-hexaen-9-ilo

$C_{31}H_{45}N_3O_8$



saracatinibum

saracatinib

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yl)oxy]quinazolin-4-amine

saracatinib

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-méthylpipérazin-1-yl)éthoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine

saracatinib

N-(5-cloro-1,3-benzodioxol-4-il)-7-[2-(4-metilpiperazin-1-il)etoxi]-5-[(oxan-4-il)oxi]quinazolin-4-amina

$C_{27}H_{32}ClN_5O_5$



semagacestatum

semagacestat

(2*S*)-2-hydroxy-3-methyl-*N*-[(2*S*)-1-{[(1*S*)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1*H*-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamide

sémagacestat

(2*S*)-2-hydroxy-3-méthyl-*N*-[(2*S*)-1-{[(1*S*)-3-méthyl-2-oxo-2,3,4,5-tétrahydro-1*H*-3-benzazépin-1-yl]amino}-1-oxopropan-2-yl]butanamide

semagacestat

(2*S*)-2-hidroxi-3-metil-*N*-[(2*S*)-1-{[(1*S*)-3-metil-2-oxo-2,3,4,5-tetrahidro-1*H*-3-benzazepin-1-il]amino}-1-oxopropan-2-il]butanamida

$C_{19}H_{27}N_3O_4$



semuloparinum natricum

semuloparin sodium

sodium salt of a low molecular mass heparin that is obtained by phosphazene promoted depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 4-deoxy-2-*O*-sulfo-α-L-*threo*-hex-4-enopyranosuronic acid structure at the non-reducing end and a 2-deoxy-6-*O*-sulfo-2-(sulfoamino)-D-glucopyranose structure at the reducing end of their chain; the molecular mass is defined by a repartition, no more than 40% is inferior to 1600 and no more than 11% is superior to 4500 Daltons, and by a mass-average value comprised between 2000 and 3000 Daltons; the degree of sulfatation is about 2.0 per disaccharidic unit

sémuloparine sodique

sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation à l'aide de phosphazène d'héparine de muqueuse intestinale de porc. La majorité des composants présente une structure acide 4-déoxy-2-*O*-sulfo-α-L-*thréo*-hex-4-énopyranosuronique à l'extrémité non réductrice et une structure 2-déoxy-6-*O*-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative du produit est définie par une répartition, au plus 40% inférieur à 1600 et au plus 11% supérieur à 4500, et une moyenne comprise entre 2000 et 3000 ; le degré de sulfatation est voisin de 2 par unité disaccharide

semuloparina sódica

sal sódica de la heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización mediante un proceso controlado en el que se utiliza fosfazeno. La mayoría de los componentes presentan la estructura ácido 4-desoxi-2-*O*-sulfo-α-L-*treo*-hex-4-enopiranosurónico en el extremo no reductor y la estructura 2-desoxi-6-*O*-sulfo-2-(sulfoamino)-D-glucopiranosa en el extremo reductor de su cadena ; la masa molecular relativa del producto se define por una distribución, en la que, como máximo, un 40% es inferior a 1600 y, como máximo, un 11% es superior a 4500, y la media está comprendida entre 2000 y 3000 ; el grado de sulfatación es aproximadamente 2 por unidad de disacárido

sivifenum

sivifene

4,4'-{[2-(2,4-dinitrophenyl)hydrazinylidene]methylene}diphenol

sivifène

4,4'-{[(2,4-dinitrophényl)diazanylidène]méthylène}diphénol

sivifeno

4,4'-{[2-(2,4-dinitrofenil)hidrazinilideno]metileno}difenol

$C_{19}H_{14}N_4O_6$



talarozolum

talarozole	*N*-{4-[2-ethyl-1-(1*H*-1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine
talarozole	*N*-{4-[(1*R*)-2-ethyl-1-(1*H*-1,2,4-triazol-1-yl)butyl]phenyl}benzothiazol-2-amine
talarozol	*N*-{4-[2-etil-1-(1*H*-1,2,4-triazol-1-il)butil]fenil}-1,3-benzotiazol-2-amina

$C_{21}H_{23}N_5S$



talmapimodum

talmapimod	2-[6-chloro-5-({(2*R*,5*S*)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl}carbonyl)-1-methyl-1*H*-indol-3-yl]-*N*,*N*-dimethyl-2-oxoacetamide
talmapimod	2-[6-chloro-5-({(2*R*,5*S*)-4-[(4-fluorophényl)méthyl]-2,5-diméthylpipérazin-1-yl}carbonyl)-1-méthyl-1*H*-indole-3-yl]-*N*,*N*-diméthyl-2-oxoacétamide
talmapimod	2-[6-cloro-5-({(2*R*,5*S*)-4-[(4-fluorofenil)metil]-2,5-dimetilpiperazin-1-il}carbonil)-1-metil-1*H*-indol-3-il]-*N*,*N*-dimetil-2-oxoacetamida

$C_{27}H_{30}ClFN_4O_3$



tanezumabum*

tanezumab

immunoglobulin G2, anti-[*Homo sapiens* nerve growth factor beta (NGFB)], humanized monoclonal antibody, RN624; gamma2 heavy chain (1-447) [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR-*Homo sapiens* IGHJ4*01) [8.7.15] (1-121) -*Homo sapiens* IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR-*Homo sapiens* IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (223-223'':224-224'':227-227'':230-230'')-tetradisulfide dimer
analgesic

tanézumab

immunoglobuline G2, anti-[*Homo sapiens* facteur de croissance beta des nerfs (NGFB)], anticorps monoclonal humanisé, RN624; chaîne lourde gamma2 (1-447) [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR-*Homo sapiens* IGHJ4*01) [8.7.15] (1-121) -*Homo sapiens* IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR-*Homo sapiens* IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (223-223'':224-224'':227-227'':230-230'')-tetradisulfure
analgésique

tanezumab

inmunoglobulina G2, anti-[*Homo sapiens* factor beta de crecimiento de los nervios (NGFB)], anticuerpo monoclonal humanizado, RN624; cadena pesada gamma2 (1-447) [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR-*Homo sapiens* IGHJ4*01) [8.7.15] (1-121) -*Homo sapiens* IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR-*Homo sapiens* IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (223-223'':224-224'':227-227'':230-230'')-tetradisulfuro
analgésico

$C_{6464}H_{9942}N_{1706}O_{2026}S_{46}$

tasimelteonum

tasimelteon

N-{[(1*R*,2*R*)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide

tasimeltéon

N-{[(1*R*,2*R*)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]méthyl}propanamide

tasimelteón

N-{[(1*R*,2*R*)-2-(2,3-dihidro-1-benzofuran-4-il)ciclopropil]metil}propanamida

$C_{15}H_{19}NO_2$



tasisulamum

tasisulam — *N*-(5-bromothiophene-2-sulfonyl)-2,4-dichlorobenzamide

tasisulam — *N*-[(5-bromothiophén-2-yl)sulfonyl]-2,4-dichlorobenzamide

tasisulam — *N*-(5-bromotiofeno-2-sulfonil)-2,4-diclorobenzamida

$C_{11}H_6BrCl_2NO_3S_2$



taspoglutidum

taspoglutide — [8-(2-amino-2-methylpropanoic acid),35-(2-amino-2-methylpropanoic acid)]human glucagon-like peptide 1 (GLP-1)-(7-36)-peptidamide
L-histidyl-2-methyl-L-alanyl-L-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysyl-2-methyl-L-alanyl-L-arginamide

taspoglutide — [8-(acide 2-amino-2-méthylpropanoïque),35-(acide 2-amino-2-méthylpropanoïque)]peptide 1 apparenté au glucagon humain (GLP-1)-(7-36)-peptidamide
L-histidyl-2-méthyl-L-alanyl-L-glutamylglycyl-L-thréonyl-L-phénylalanyl-L-thréonyl-L-séryl-L-aspartyl-L-valyl-L-séryl-L-séryl-L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysyl-L-glutamyl-L-phénylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysyl-2-méthyl-L-alanyl-L-arginamide

taspoglutida — [8-(ácido 2-amino-2-metilpropanoico),35-(ácido 2-amino-2-metilpropanoico)]péptido 1 relacionado con el glucagón humano-(7-36)-peptidamida
L-histidil-2-metil-L-alanil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-aspartil-L-valil-L-seril-L-seril-L-tirosil-L-leucil-L-glutamilglicil-L-glutaminil-L-alanil-L-lisil-L-glutamil-L-fenilalanil-L-isoleucil-L-alanil-triptofil-L-leucil-L-valil-L-lisil-2-metil-L-alanil-L-arginamida

$C_{152}H_{232}N_{40}O_{45}$

H—His(7)—Aib—Glu—Gly(10)—Thr—Phe—Thr—Ser—Asp—Val—Ser—Ser—
Tyr—Leu(20)—Glu—Gly—Gln—Ala—Ala—Lys—Glu—Phe—Ile—Ala(30)—
Trp—Leu—Val—Lys—Aib—Arg—NH_2



tecovirimatum

tecovirimat — *N*-[1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[*f*]isoindol-2(1*H*)-yl]-4-(trifluoromethyl)benzamide

técovirimat — *N*-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-éthénocyclopropa[*f*]isoindol-2(1*H*)-yl)-4-(trifluorométhyl)benzamide

tecovirimat — *N*-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahidro-4,6-etenociclopropa[*f*]isoindol-2(1*H*)-il)-4-(trifluorometil)benzamida

$C_{19}H_{15}F_3N_2O_3$



teneligliptinum

teneligliptin — {(2*S*,4*S*)-4-[4-(3-methyl-1-phenyl-1*H*-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone

ténéligliptine — {(2*S*,4*S*)-4-[4-(3-méthyl-1-phényl-1*H*-pyrazol-5-yl)pipérazin-1-yl]pyrrolidin-2-yl}(thiazolidin-3-yl)méthanone

teneligliptina — {(2*S*,4*S*)-4-[4-(1-fenil-3-metil-1*H*-pirazol-5-il)piperazin-1-il]pirrolidin-2-il}(1,3-tiazolidin-3-il)metanona

$C_{22}H_{30}N_6OS$



tildipirosinum

tildipirosin — (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-[2-(piperidin-1-yl)ethyl]-15-[(piperidin-1-yl)methyl]-2,10-dioxooxacyclohexadeca-11,13-dien-6-yl β-D-glucopyranoside

tildipirosine — (+)-(4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-6-{[3,6-didésoxy-3-(diméthylamino)-β-D-glucopyranosyl]oxy}-16-éthyl-4-hydroxy-5,9,13-triméthyl-7-[2-(pipéridin-1-yl)éthyl]-15-(pipéridin-1-ylméthyl)oxacyclohexadéca-11,13-diène-2,10-dione

tildipirosina — β-D-glucopiranosido de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-16-etil-4-hidroxi-5,9,13-trimetil-7-[2-(piperidin-1-il)etil]-15-[(piperidin-1-il)metil]-2,10-dioxooxaciclohexadeca-11,13-dien-6-ilo

$C_{41}H_{71}N_3O_8$



tosedostatum

tosedostat	cyclopentyl (2*S*)-2-{(2*R*)-2-[(*S*)-hydroxy(hydroxycarbamoyl)methyl]-4-methylpentanamido}-2-phenylacetate
tosédostat	(2*S*)-2-({(2*R*)-2-[(1*S*)-1-hydroxy-2-(hydroxyamino)-2-oxoéthyl]-4-méthylpentanoyl}amino)-2-phénylacétate de cyclopentyle
tosedostat	(2*S*)-2-{(2*R*)-2-[(*S*)-hidroxi(hidroxicarbamoil)metil]-4-metilpentanamido}-2-fenilacetato de ciclopentilo

$C_{21}H_{30}N_2O_6$



troplasminogenum alfa #

troplasminogen alfa	thrombin-activable plasminogen: endo-[(558a(*559*)-558h(*365*))-human coagulation factor XI-(363-370)-peptide]-des-(559-562)-[606(*610*)-lysine,623(*627*)-lysine]human plasminogen, glycoform α
troplasminogène alfa	plasminogène activable par la thrombine : endo-[(558a(*559*)-558h(*365*))-facteur XI de coagulation humain-(363-370)-peptide]-dès-(559-562)-[606(*610*)-lysine,623(*627*)-lysine]plasminogène humain, glycoforme α
troplasminógeno alfa	plasminógeno activable por la trombina : endo-[(558a(*559*)-558h(*365*))-facteur XI de coagulación humano-(363-370)-péptido]-des-(559-562)-[606(*610*)-lisina,623(*627*)-lisina] plasminógeno humano, glicoforma α

$C_{3875}H_{5917}N_{1107}O_{1190}S_{58}$

```
EPLDDYVNTQ  GASLFSVTKK  QLGAGSIEEC  AAKCEEDEEF  TCRAFQYHSK  50
EQQCVIMAEN  RKSSIIIRMR  DVVLFEKKVY  LSECKTGNGK  NYRGTMSKTK  100
NGITCQKWSS  TSPHRPRFSP  ATHPSEGLEE  NYCRNPDNDP  QGPWCYTTDP  150
EKRYDYCDIL  ECEEECMHCS  GENYDGKISK  TMSGLECQAW  DSQSPHAHGY  200
IPSKFPNKNL  KKNYCRNPDR  ELRPWCFTTD  PNKRWELCDI  PRCTTPPPSS  250
GPTYQCLKGT  GENYRGNVAV  TVSGHTCQHW  SAQTPHTHNR  TPENFPCKNL  300
DENYCRNPDG  KRAPWCHTTN  SQVRWEYCKI  PSCDSSPVST  EQLAPTAPPE  350
LTPVVQDCYH  GDGQSYRGTS  STTTGKKCQ   SWSSMTPHRH  QKTPENYPNA  400
GLTMNYCRNP  DADKGPWCFT  TDPSVRWEYC  NLKKCSGTEA  SVVAPPPVVL  450
LPDVETPSEE  DCMFGNGKGY  RGKRATTVTG  TPCQDWAAQE  PHRHSIFTPE  500
TNPRAGLEKN  YCRNPDGDVG  GPWCYTTNPR  KLYDYCDVPQ  CAAPSFDCGK  550
PQVEPKKCTT  KIKPRIVGGC  VAHPHSWPWQ  VSLRTRFGMH  FCGGTLISPE  600
WVLTAAHCLK  KSPRPSSYKV  ILGAHQKVNL  EPHVQEIEVS  RLFLEPTRKD  650
IALLKLSSPA  VITDKVIPAC  LPSPNYVVAD  RTECFITGWG  ETQGTFGAGL  700
LKEAQLPVIE  NKVCNRYEFL  NGRVQSTELC  AGHLAGGTDS  CQGDSGGPLV  750
CFEKDKYILQ  GVTSWGLGCA  RPNKPGVYVR  VSRFVTWIEG  VMRNN       795
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

30-54 34-42 84-162 105-145 133-157 166-243 169-297 187-226
215-238 256-333 277-316 305-328 358-435 379-418 407-430 462-541
483-524 512-536 548-670 558-570 592-608 684-751 714-730 741-769

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Ser-249 Asn-289 Thr-346

ustekinumabum #

ustekinumab — immunoglobulin G1, anti-[*Homo sapiens* interleukin 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF p40)], *Homo sapiens* monoclonal antibody, CNTO 1275; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

ustékinumab — immunoglobulin G1, anti-[*Homo sapiens* interleukine 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF2 p40)], *Homo sapiens* anticorps monoclonal, CNTO 1275; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

ustekinumab — inmunoglobulina G1, anti-[*Homo sapiens* interleukina 12B (IL12B, IL12 p40, factor 2 estimulante de las células *natural killer* NKSF2, factor 2 citotóxico de la maduraciòn de linfocitos, CLMF2, CMLF2 p40)], *Homo sapiens* anticuerpo monoclonal, CNTO 1275; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

$C_{6482}H_{10004}N_{1712}O_{2016}S_{46}$

vadimezanum

vadimezan — 2-(6,7-dimethyl-9-oxo-9*H*-xanthen-4-yl)acetic acid

vadimézan — acide (5,6-diméthyl-9-oxo-9*H*-xanthén-4-yl)acétique

vadimezan — ácido 2-(6,7-dimetil-9-oxo-9*H*-xanten-4-ilo)ácetico

$C_{17}H_{14}O_4$



velneperitum

velneperit	(1*r*,4*s*)-4-(1,1-dimethylethanesulfonamido)-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclohexanecarboxamide
velnépérit	(1*r*,4*s*)-4-(1,1-diméthyléthanesulfonamido)-*N*-[5-(trifluorométhyl)pyridin-2-yl]cyclohexanecarboxamide
velneperit	(1*r*,4*s*)-4-(1,1-dimetiletanosulfonamido)-*N*-[5-(trifluorometil)piridin-2-il]ciclohexanocarboxamida

$C_{17}H_{24}F_3N_3O_3S$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales recommandées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

	delete	*replace*
p. 7	cipamfylline	cipamfyllinum

Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

	delete	*replace*
p. 256	netupitant	netupitantum

Recommended International Nonproprietary Names (Rec. INN): List 57
Dénominations communes internationales recommandées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 55 **aclidinii bromidum**

aclidinium bromide	*replace the chemical name by the following* (3*R*)-3-{[hydroxydi(thiophen-2-yl)acetyl]oxy}-1-(3-phenoxypropyl)-1λ^5-azabicyclo[2.2.2]octan-1-ylium bromide
bromure d'aclidinium	*remplacer le nom chimique par le suivant* bromure de (3*R*)-3-{[hydroxydi(thiophén-2-yl)acétyl]oxy}-1-(3-phénoxypropyl)-1λ^5-azabicyclo[2.2.2]octan-1-ylium

Recommended International Nonproprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)

p. 264 **aclidinii bromidum**

bromuro de aclidinio	*sustitúyase el nombre químico por el siguiente* bromuro de (3*R*)-1-(3-fenoxipropil)-3-{[hidroxidi(tiofen-2-yl)acetil]oxi}-1λ^5-azabiciclo[2.2.2]octan-1-ilio

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 63	*delete*	*replace*
	rabeximod	rabeximodum

Recommended International Non Proprietary Names (Rec. INN): List 60
Dénominations communes internationales recommandées (DCI Rec.): Liste 60
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 60
(WHO Drug Information, Vol. 22, No. 3, 2008)

p. 232	*delete*	*replace*
	eribaxaban	eribaxabanum

Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.